Adalimumab Versus <scp>JAK</scp> Inhibitors in Juvenile Idiopathic Arthritis

Tsai‐Yi Hung, Yung‐Heng Lee, Brian Shiian Chen, Chen Dong, An‐Ping Huo

Open source

DOI
10.1111/1756-185x.70368
Published
2025-07
Container
International Journal of Rheumatic Diseases
Publisher
Wiley
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1111/1756-185x.70368,
  title = {Adalimumab Versus
                    <scp>JAK</scp>
                    Inhibitors in Juvenile Idiopathic Arthritis},
  author = {Tsai‐Yi Hung and Yung‐Heng Lee and Brian Shiian Chen and Chen Dong and An‐Ping Huo},
  year = {2025},
  journal = {International Journal of Rheumatic Diseases},
  doi = {10.1111/1756-185x.70368},
  url = {https://doi.org/10.1111/1756-185x.70368}
}

RIS

TY  - JOUR
TI  - Adalimumab Versus
                    <scp>JAK</scp>
                    Inhibitors in Juvenile Idiopathic Arthritis
AU  - Tsai‐Yi Hung
AU  - Yung‐Heng Lee
AU  - Brian Shiian Chen
AU  - Chen Dong
AU  - An‐Ping Huo
PY  - 2025
JO  - International Journal of Rheumatic Diseases
DO  - 10.1111/1756-185x.70368
UR  - https://doi.org/10.1111/1756-185x.70368
ER  - 

APA

Hung, T., Lee, Y., Chen, B. S., Dong, C., & Huo, A. (2025). Adalimumab Versus <scp>JAK</scp> Inhibitors in Juvenile Idiopathic Arthritis. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.70368

Source records